Published in Antivir Ther on January 01, 2009
Comparison of HIV-1 genotypic resistance test interpretation systems in predicting virological outcomes over time. PLoS One (2010) 1.33
Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: a retrospective cohort study. BMC Infect Dis (2012) 1.26
Clinical management of HIV drug resistance. Viruses (2011) 1.02
Antiretroviral therapy optimisation without genotype resistance testing: a perspective on treatment history based models. PLoS One (2010) 0.98
A Rough Set-Based Model of HIV-1 Reverse Transcriptase Resistome. Bioinform Biol Insights (2009) 0.90
Machine Learning and Decision Support in Critical Care. Proc IEEE Inst Electr Electron Eng (2016) 0.88
Sparse Representation for Prediction of HIV-1 Protease Drug Resistance. Proc SIAM Int Conf Data Min (2013) 0.86
A prognostic model for estimating the time to virologic failure in HIV-1 infected patients undergoing a new combination antiretroviral therapy regimen. BMC Med Inform Decis Mak (2011) 0.82
Clinical evaluation of Rega 8: an updated genotypic interpretation system that significantly predicts HIV-therapy response. PLoS One (2013) 0.82
Can linear regression modeling help clinicians in the interpretation of genotypic resistance data? An application to derive a lopinavir-score. PLoS One (2011) 0.81
Scoring methods for building genotypic scores: an application to didanosine resistance in a large derivation set. PLoS One (2013) 0.80
A pilot study investigating changes in neural processing after mindfulness training in elite athletes. Front Behav Neurosci (2015) 0.78
Investigation of Super Learner Methodology on HIV-1 Small Sample: Application on Jaguar Trial Data. AIDS Res Treat (2012) 0.77
The individualized genetic barrier predicts treatment response in a large cohort of HIV-1 infected patients. PLoS Comput Biol (2013) 0.77
IDEPI: rapid prediction of HIV-1 antibody epitopes and other phenotypic features from sequence data using a flexible machine learning platform. PLoS Comput Biol (2014) 0.76
Combining Kernel and Model Based Learning for HIV Therapy Selection. AMIA Jt Summits Transl Sci Proc (2017) 0.75
Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One (2009) 8.37
An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics (2005) 5.60
The molecular population genetics of HIV-1 group O. Genetics (2004) 4.53
Human T-lymphotropic virus 1: recent knowledge about an ancient infection. Lancet Infect Dis (2007) 3.80
Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis (2005) 3.52
Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med (2005) 3.17
Mechanisms of hypergammaglobulinemia and impaired antigen-specific humoral immunity in HIV-1 infection. Blood (2003) 2.70
Clinical usefulness, angiographic characteristics, and safety evaluation of intracoronary acetylcholine provocation testing among 921 consecutive white patients with unobstructed coronary arteries. Circulation (2014) 2.65
U.S. Human immunodeficiency virus type 1 epidemic: date of origin, population history, and characterization of early strains. J Virol (2003) 2.64
Transmission of drug-resistant HIV-1 is stabilizing in Europe. J Infect Dis (2009) 2.60
Complete genomic sequence of human coronavirus OC43: molecular clock analysis suggests a relatively recent zoonotic coronavirus transmission event. J Virol (2005) 2.35
Tracing the origin and history of the HIV-2 epidemic. Proc Natl Acad Sci U S A (2003) 2.31
High prevalence of a pathological response to acetylcholine testing in patients with stable angina pectoris and unobstructed coronary arteries. The ACOVA Study (Abnormal COronary VAsomotion in patients with stable angina and unobstructed coronary arteries). J Am Coll Cardiol (2012) 2.24
Clinically validated genotype analysis: guiding principles and statistical concerns. Antivir Ther (2004) 2.14
A standardized framework for accurate, high-throughput genotyping of recombinant and non-recombinant viral sequences. Nucleic Acids Res (2009) 2.06
A genotypic drug resistance interpretation algorithm that significantly predicts therapy response in HIV-1-infected patients. Antivir Ther (2002) 1.92
Early virologic rebound in a pilot trial of ritonavir-boosted atazanavir as maintenance monotherapy. J Acquir Immune Defic Syndr (2007) 1.88
Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. Pharmacogenet Genomics (2006) 1.80
HIV care in the Swedish-Danish HIV cohort 1995-2010, closing the gaps. PLoS One (2013) 1.77
Prevalence and correlates of nonadherence to antiretroviral therapy in a population of HIV patients using Medication Event Monitoring System. AIDS Patient Care STDS (2004) 1.75
Recombination confounds the early evolutionary history of human immunodeficiency virus type 1: subtype G is a circulating recombinant form. J Virol (2007) 1.74
The development of artificial neural networks to predict virological response to combination HIV therapy. Antivir Ther (2007) 1.71
Automated subtyping of HIV-1 genetic sequences for clinical and surveillance purposes: performance evaluation of the new REGA version 3 and seven other tools. Infect Genet Evol (2013) 1.69
Activation, exhaustion, and persistent decline of the antimicrobial MR1-restricted MAIT-cell population in chronic HIV-1 infection. Blood (2012) 1.69
Accumulation of DC-SIGN+CD40+ dendritic cells with reduced CD80 and CD86 expression in lymphoid tissue during acute HIV-1 infection. AIDS (2002) 1.67
Combinatorial analysis and algorithms for quasispecies reconstruction using next-generation sequencing. BMC Bioinformatics (2011) 1.62
Genetic variability and molecular evolution of the human respiratory syncytial virus subgroup B attachment G protein. J Virol (2005) 1.60
DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A. PLoS One (2010) 1.59
Tracing the HIV-1 subtype B mobility in Europe: a phylogeographic approach. Retrovirology (2009) 1.58
Phylogenetic surveillance of viral genetic diversity and the evolving molecular epidemiology of human immunodeficiency virus type 1. J Virol (2007) 1.57
Diagnostic value of different adherence measures using electronic monitoring and virologic failure as reference standards. AIDS Patient Care STDS (2008) 1.54
Efavirenz plasma concentrations in HIV-infected patients: inter- and intraindividual variability and clinical effects. Ther Drug Monit (2004) 1.53
A synthetic HIV-1 Rev inhibitor interfering with the CRM1-mediated nuclear export. Proc Natl Acad Sci U S A (2002) 1.53
Quantifying differences in the tempo of human immunodeficiency virus type 1 subtype evolution. J Virol (2009) 1.49
Relating increasing hantavirus incidences to the changing climate: the mast connection. Int J Health Geogr (2009) 1.48
Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy. AIDS (2002) 1.48
Molecular evolution and circulation patterns of human respiratory syncytial virus subgroup a: positively selected sites in the attachment g glycoprotein. J Virol (2004) 1.48
Obesity, inflammation and brachial artery flow-mediated dilatation: therapeutic targets in patients with microvascular angina (cardiac syndrome X). Cardiovasc Drugs Ther (2012) 1.43
Protease mutation M89I/V is linked to therapy failure in patients infected with the HIV-1 non-B subtypes C, F or G. AIDS (2005) 1.41
Prognostic value of left atrial expansion index and exercise-induced change in atrial natriuretic peptide as long-term predictors of atrial fibrillation recurrence. Europace (2012) 1.40
European recommendations for the clinical use of HIV drug resistance testing: 2011 update. AIDS Rev (2011) 1.38
HIV-1 protease and reverse transcriptase mutation patterns responsible for discordances between genotypic drug resistance interpretation algorithms. J Acquir Immune Defic Syndr (2003) 1.38
Hepatitis C virus evolutionary patterns studied through analysis of full-genome sequences. J Mol Evol (2002) 1.38
The incidence of multidrug and full class resistance in HIV-1 infected patients is decreasing over time (2001-2006) in Portugal. Retrovirology (2008) 1.38
Feasibility and effectiveness of indicator condition-guided testing for HIV: results from HIDES I (HIV indicator diseases across Europe study). PLoS One (2013) 1.36
Molecular footprint of drug-selective pressure in a human immunodeficiency virus transmission chain. J Virol (2005) 1.36
3-year follow-up of patients with coronary artery spasm as cause of acute coronary syndrome: the CASPAR (coronary artery spasm in patients with acute coronary syndrome) study follow-up. J Am Coll Cardiol (2011) 1.33
Comparison of HIV-1 genotypic resistance test interpretation systems in predicting virological outcomes over time. PLoS One (2010) 1.33
Evolution of raltegravir resistance during therapy. J Antimicrob Chemother (2009) 1.33
Use of electronic monitoring induces a 40-day intervention effect in HIV patients. J Acquir Immune Defic Syndr (2006) 1.33
Severe functional impairment and elevated PD-1 expression in CD1d-restricted NKT cells retained during chronic HIV-1 infection. Eur J Immunol (2009) 1.31
A comparison of three computational modelling methods for the prediction of virological response to combination HIV therapy. Artif Intell Med (2009) 1.31
HIV-1 subtype distribution and its demographic determinants in newly diagnosed patients in Europe suggest highly compartmentalized epidemics. Retrovirology (2013) 1.30
A novel methodology for large-scale phylogeny partition. Nat Commun (2011) 1.29
Early immune activation in gut-associated and peripheral lymphoid tissue during acute HIV infection. AIDS (2007) 1.28
The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes. J Acquir Immune Defic Syndr (2006) 1.27
Comparative determination of HIV-1 co-receptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop RNA and DNA genotyping. Retrovirology (2010) 1.26
Molecular epidemiology of HIV-1 subtypes in India: origin and evolutionary history of the predominant subtype C. PLoS One (2012) 1.25
Low prevalence of transmitted drug resistance in patients newly diagnosed with HIV-1 infection in Sweden 2003-2010. PLoS One (2012) 1.24
Analysis of the serotype and genotype correlation of VP1 and the 5' noncoding region in an epidemiological survey of the human enterovirus B species. J Clin Microbiol (2004) 1.22
Naturally occurring hepatitis C virus (HCV) NS3/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy. J Antimicrob Chemother (2012) 1.21
Construction, training and clinical validation of an interpretation system for genotypic HIV-1 drug resistance based on fuzzy rules revised by virological outcomes. Antivir Ther (2004) 1.21
Hepatitis C virus genotypes distribution and transmission risk factors in Luxembourg from 1991 to 2006. World J Gastroenterol (2008) 1.19
Identification in gelada baboons (Theropithecus gelada) of a distinct simian T-cell lymphotropic virus type 3 with a broad range of Western blot reactivity. J Gen Virol (2004) 1.18
Rising prevalence of HIV-1 non-B subtypes in Belgium: 1983-2001. J Acquir Immune Defic Syndr (2004) 1.17
Profile of resistance of human immunodeficiency virus to mannose-specific plant lectins. J Virol (2004) 1.17
Limitations to contact tracing and phylogenetic analysis in establishing HIV type 1 transmission networks in Cuba. AIDS Res Hum Retroviruses (2007) 1.16
Mapping sites of positive selection and amino acid diversification in the HIV genome: an alternative approach to vaccine design? Genetics (2004) 1.15
Minimal important differences for interpreting health-related quality of life scores from the EORTC QLQ-C30 in lung cancer patients participating in randomized controlled trials. Support Care Cancer (2010) 1.15
Assessment of automated genotyping protocols as tools for surveillance of HIV-1 genetic diversity. AIDS (2006) 1.14
Different epidemic potentials of the HIV-1B and C subtypes. J Mol Evol (2005) 1.12
Low levels of perforin expression in CD8+ T lymphocyte granules in lymphoid tissue during acute human immunodeficiency virus type 1 infection. J Infect Dis (2002) 1.10
Tenofovir resistance and resensitization. Antimicrob Agents Chemother (2003) 1.10
A genotypic resistance assay for the detection of drug resistance in the human immunodeficiency virus type 1 envelope gene. J Virol Methods (2005) 1.10
Phylodynamics of the HIV-1 CRF02_AG clade in Cameroon. Infect Genet Evol (2011) 1.10
Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA study group. New Microbiol (2012) 1.10
In vivo characteristics of human immunodeficiency virus type 1 intersubtype recombination: determination of hot spots and correlation with sequence similarity. J Gen Virol (2003) 1.09
Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of human immunodeficiency virus are subtype dependent. Antimicrob Agents Chemother (2006) 1.08
Predicting the response to combination antiretroviral therapy: retrospective validation of geno2pheno-THEO on a large clinical database. J Infect Dis (2009) 1.07
Multiparametric bioinformatics distinguish the CD4/CD8 ratio as a suitable laboratory predictor of combined T cell pathogenesis in HIV infection. J Immunol (2014) 1.07
Comparison of classifier fusion methods for predicting response to anti HIV-1 therapy. PLoS One (2008) 1.07